Medpace Holdings, Inc. with ticker code (MEDP) have now 8 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $480.00 and $395.00 calculating the mean target share price we have $445.66. (at the time of writing). Given that the stocks previous close was at $402.99 and the analysts are correct then we can expect a percentage increase in value of 10.6%. It’s also worth noting that there is a 50 day moving average of $393.96 and the 200 day MA is $329.54. The company has a market capitalization of 12.41B. The stock price is currently at: $400.63 USD
The potential market cap would be $13,727,199,295 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 40.84, revenue per share of $63.98 and a 13.89% return on assets.
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focuses on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. It also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
